Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
about
Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance MutationsCrystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 ProteaseHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsHIV protease inhibitors: a review of molecular selectivity and toxicityTiming the emergence of resistance to anti-HIV drugs with large genetic barriersGenotypic testing for human immunodeficiency virus type 1 drug resistance.Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesInteraction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.New anti-HIV agents and targets.Early factors in successful anti-HIV treatment.Current and Novel Inhibitors of HIV ProteaseTipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.Initial therapy for human immunodeficiency virus: broadening the options.Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialAntiretroviral drugs: critical issues and recent advancesTipranavir: a novel second-generation nonpeptidic protease inhibitor.Emerging anti-HIV drugs.Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.Tipranavir: a protease inhibitor for HIV salvage therapy.Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersReview of tipranavir in the treatment of drug-resistant HIV.Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsTipranavir: a new option for the treatment of drug-resistant HIV infection.P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.Tipranavir in the protease inhibitors arena.Human Immunodeficiency Virus Gag and protease: partners in resistance.Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.Strategies in the Design of Antiviral DrugsTipranavir: a novel protease inhibitor for HIV therapyInhibitors of HIV-1 protease: 10 years afterNew HIV protease inhibitors for drug-resistant viruses
P2860
Q27644072-1343E23A-6981-4F7E-B905-89D7BA65A385Q27646453-D4C166C5-9CA5-4258-B76B-6DF096FC0AC4Q27650325-D6013D6D-2BA1-41D3-AFD5-2B87A402C3C7Q28082749-66F16AA7-FC4C-44DB-89B6-9E068BB0C6CBQ28474857-A77DCC7F-D684-4155-B1E4-DC93984B94F9Q33906239-02227E81-4F6B-4022-BAC8-CE67C6CC79CBQ34050693-679BA7D8-BE30-41FE-8F3F-6BC0DEF36600Q34102058-2D6EEBD3-D9F5-4590-8CEB-0CC2B6BFB5A3Q34228277-1D57E035-89BF-4A29-B484-25B60B1B3578Q34633457-14C7F53C-1EB2-4382-B3BB-1C79294C165FQ34944447-58F70239-2191-454E-8FC2-CF8B243A2A29Q35207282-772ACD03-CA00-45BA-821F-445DB01DED4EQ35259915-AB140AD1-9FE7-45D6-B598-9F69F398A31CQ35570956-75AA0D57-3FE1-4ACB-9107-E456DB7B42D2Q35759609-F44009B4-3D7F-48EC-AD4F-E6377DD7B919Q35885190-8946C554-3A2A-4D51-B2A1-5F8B2E3B7231Q36020992-32765EF0-F90F-4604-9970-690C98A32835Q36066195-4BA99081-DFCD-40C9-80CA-69438DD3ECEEQ36150601-045B8AD6-C41B-4900-9B1C-1C41D121A23FQ36375914-AF15629B-395E-4648-99E8-5E10A2F24064Q36414526-6BE10E42-6479-434A-97E8-1A3506071A49Q36513619-9FAB6CC9-22AB-48E0-B21C-3B44B6F30D7EQ36558221-A7D51C5F-7D8C-4383-A98C-59467927BAA3Q36642990-D9A5B804-C98E-4898-9649-3FBC7124C64FQ36870850-0132C104-1B36-4C50-90AE-5FD960F83076Q36916096-7BDA82D3-C744-48AF-A432-9F43A6C8BA92Q37732337-07EB468E-8EFE-4C4A-B3DF-CD7E0E601358Q37963591-F7D44D80-8967-4E24-9FE4-3C2AE503FF3EQ38032330-739A8D8B-BCD7-4354-83DE-DD1181336739Q39290078-47DCD98F-B113-4096-937D-BB555F3E18FFQ42003165-FCF5DA40-B760-492C-8186-D6288415CDB6Q42910139-C49F7A73-EFF4-4AC1-9460-550BB8D7B97EQ43818113-80B9FAA6-BF0D-4977-82EF-A42738486E3EQ43856149-D9F7D021-27D3-4C24-8D3A-07DE6A9AEC43Q45245263-C7E845E9-D457-4730-BAEF-1DA9D5A823D7Q46990276-4DCCA566-2681-4A71-B1DA-1E2E62730254Q56786281-EAB5843D-F6C0-4583-BB69-D4AEA3F5C07CQ58388976-A6470070-C6D5-49D5-8C7B-FC0A9162E5F9Q58389026-8CA20CD8-678C-4A2C-8A1C-5537FC8CBEB7Q58389032-071F28EC-8755-4B7B-A9E0-7DA061D1101C
P2860
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@ast
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@en
type
label
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@ast
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@en
prefLabel
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@ast
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@en
P2093
P1433
P1476
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
@en
P2093
B A Larder
C H van den Eynde
W W Freimuth
P304
P356
10.1097/00002030-200009080-00009
P407
P577
2000-09-01T00:00:00Z